# US 2014/0274951 A1 · Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0274951 A1
- Document ID: US20140274951A1
- Status: Published application
- Kind: A1
- Application number: 14/209,460
- Filed: 2014-03-13
- Published: 2014-09-18
- Earliest claimed: 2013-03-14
- Assignees: Albany Molecular Research, Inc.
- Applicants: Albany Molecular Research, Inc.
- Inventors: Peter R. Guzzo; David D. Manning
- Web page: https://patentgrep.com/patent/US20140274951A1

## CPC

- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 47/551: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07D 519/04: Dimeric indole alkaloids, e.g. vincaleucoblastine
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.

## Claims

### Claim 1

A conjugate compound of formula (I):
wherein
L is a cell-targeting ligand;
T is a therapeutic agent, with the proviso that T is not CAS Registry No. 115834-23-6 (SF2446A1) or derivatives or analogues thereof;
J is a linker group;
X is independently selected from the group consisting of:
(1) a bond;
(2) O;
(3)
which is independently and optionally substituted from 1 to 2 times with R8, wherein the wavy lines indicate point of attachment sites and * is the point of attachment to J and ** is the point of attachment to Si; and
(4)
which is independently and optionally substituted from 1 to 2 times with R8, wherein the wavy lines indicate point of attachment sites and * is the point of attachment to J and ** is the point of attachment to Si;
Q is —(CH2)n—, —CH2CHR1CH2—, —CH2CR5R6CH2—, —CH2CHR1CH2CH2—, —CH2CH2CHR1CH2CH2—, —CH2X1CH2—, or —CH2CH2X1CH2CH2—;
R1 is C1-6 alkyl, aryl, heteroaryl, OR5, NR5R6, or —N(COR2)R7, each of which is optionally substituted with R8;
R2 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with R8;
R3 is H, C1-6 alkyl, C3-6 cycloalkyl, or —COR4, each of which is optionally substituted with R8;
R4 is H, C1-6 alkyl, or C3-6 cycloalkyl, each of which is optionally substituted with R8;
R5 is H or C1-6 alkyl optionally substituted with R8;
R6 is H or C1-6 alkyl optionally substituted with R8; or
R5 and R6 are taken together with the nitrogen to which they are attached to form a five- to seven-membered heterocyclic ring, which may be saturated or unsaturated and comprises from 1 to 5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and is optionally substituted from 1 to 4 times with a substituent selected independently at each occurrence thereof from the group consisting of halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 alkoxy;
R7 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with R8;
R8 is H, NO2, CN, halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, aryl, heteroaryl, COOR9, COR9, C(O)NR9R10, COONR9R10, SO2R9, SO2NR9R10, or OR9;
R9 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, wherein the C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
R10 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, wherein the C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy; or
R9 and R10 are taken together with the nitrogen to which they are attached to form a five- to seven-membered heterocyclic ring, which may be saturated or unsaturated and comprises from 1 to 5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and is optionally substituted from 1 to 4 times with a substituent selected independently at each occurrence thereof from the group consisting of halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 alkoxy;
X1 is O, S, SO, SO2, or NR3;
n is 1 to 5; and
m is 1 to 8.

### Claim 2 (depends on 1)

The conjugate compound according to claim 1, wherein J is —Z—Y2—C(O)—Y1—;
Z is
wherein the wavy lines indicate point of attachment sites and * is the point of attachment to L and ** is the point of attachment to Y2;
Y1 is C1-6 alkylene or —(X2—CH2—CH2)l—, each of which is optionally substituted with R8;
Y2 is C1-6 alkylene or —(CH2CH2(X3))q—, each of which is optionally substituted with R8;
X2 is independently selected from the group consisting of:
(1) a bond;
(2) (CH2)k;
(3) O; and
(4) NR12;
X3 is independently selected from the group consisting of:
(1) a bond;
(2) (CH2)k;
(3) O; and
(4) NR12;
R11 is H, C1-6 alkyl, C1-6 hydroxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, aryl, or heteroaryl, each of which is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
R12 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, or C1-6 hydroxyalkyl;
k is 1 to 3;
l is 1 to 10; and
q is 1 to 10.

### Claim 3 (depends on 1)

The conjugate compound according to claim 1, wherein J is —Z—Y3—;
Z is
wherein the wavy lines indicate point of attachment sites and * is the point of attachment to L and ** is the point of attachment to Y3;
Y3 is selected from the group consisting of C1-6 alkylene, C3-C8 carbocyclyl, O(CH2)r, arylene, O(CH2)r-arylene, -arylene-(CH2)r—, (CH2)r—(C3-8 carbocyclyl), —(C3-8 carbocyclyl)-(CH2)r, C3-8 heterocyclyl, (CH2)r—(C3-8 heterocyclyl), —(C3-8 heterocyclyl)-(CH2)r, —((X4)(X5)(CH2)r(X6)(CH2)r)s—, and —((X4)(X5)(CH2)r(X6)(X7)(CH2)r)s—, each of which is optionally substituted with R8;
X4, X5, X6, and X7 are each independently selected from the group consisting of a bond, (CH2)k, O, C(O), S, NR19, C(O)O, and C(O)NR19;
R11 is H, C1-6 alkyl, C1-6 hydroxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, aryl, or heteroaryl, each of which is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
R19 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, or C1-6 hydroxyalkyl;
each r is 0 to 16; and
s is 1 to 10.

### Claim 4 (depends on 1)

The conjugate compound according to claim 1, Q is —(CH2)n— and n is 1 to 5.

### Claim 5 (depends on 1)

The conjugate compound according to claim 1, wherein J further comprises a thiol-containing spacer.

### Claim 6 (depends on 1)

The conjugate compound according to claim 1, wherein L is a protein, a peptide, an amino acid, a receptor ligand, a hormone, or a growth factor.

### Claim 7 (depends on 6)

The conjugate compound according to claim 6, wherein L is selected from the group consisting of an antibody, an antibody fragment, scFv-Fc, minibody, diabody, scFv, folic acid, bombesin, EDG, transferrin, gastrin, gastrin-releasing peptide, platelet-derived growth factor, IL-2, IL-6, TFG-alpha, TFG-beta, VGF, insulin, and insulin-like growth factors I and II.

### Claim 8 (depends on 6)

The conjugate compound according to claim 6, wherein L is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(35):
(1) BMPR1B (bone morphogenetic protein receptor-type IB, Genbank Accession No. NM—001203);
(2) E16 (LAT1, SLC7A5, Genbank Accession No. NM—003486);
(3) STEAP1 (six transmembrane epithelial antigen of prostate, Genbank Accession No. NM—012449);
(4) 0772P (CA125, MUC16, Genbank Accession No. AF361486);
(5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin, Genbank Accession No. NM—005823);
(6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b, Genbank Accession No. NM—006424);
(7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5bHlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembranedomain (TM) and short cytoplasmic domain, (semaphorin) 5B, Genbank Accession No. AB040878);
(8) PSCA h1g (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene, Genbank Accession No. AY358628);
(9) ETBR (Endothelin type B receptor, Genbank Accession No. AY275463);
(10) MSG783 (RNF124, hypotheticalproteinFLJ20315, Genbank Accession No. NM—017763);
(11) STEAP2 (HGNC—8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostatecancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelialantigen of prostate 2, six transmembrane prostate protein, Genbank Accession No. AF455138);
(12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potentialcation channel, subfamily M, member 4, Genbank Accession No. NM—017636);
(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor, Genbank Accession No. NP—003203 or NM—003212);
(14) CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs.73792 Genbank Accession No. M26004);
(15) CD79b (CD79B, CD7913, IGb (immunoglobulin-associated beta), B29, Genbank Accession No. NM—000626);
(16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchorprotein 1a), SPAP1B, SPAP1C, Genbank Accession No. NM—030764);
(17) HER2 (Genbank Accession No. M11730);
(18) NCA (Genbank Accession No. M18728);
(19) MDP (Genbank Accession No. BC017023);
(20) IL20Rα (Genbank Accession No. AF184971);
(21) Brevican (Genbank Accession No. AF229053);
(22) Ephb2R (Genbank Accession No. NM—004442);
(23) ASLG659 (Genbank Accession No. AX092328);
(24) PSCA (Genbank Accession No. AJ297436);
(25) GEDA (Genbank Accession No. AY260763);
(26) BAFF-R (B cell-activating factor receptor, BLyS receptor 3, BR3, Genbank Accession No. NP 443177.1);
(27) CD22 (B-cell receptor CD22-B isoform, Genbank Accession No. NP-001762.1);
(28) CD79a (CD79A, CD79α, immunoglobulin-associated alpha, a B cell-specific protein that covalently interacts with Ig beta (CD79B) and forms a complex on the surface with Ig M molecules, transduces a signal involved in B-cell differentiation, Genbank Accession No. NP—001774.1);
(29) CXCR5 (Burkitt's lymphoma receptor 1, a G protein-coupled receptor that is activated by the CXCL13 chemokine, functions in lymphocyte migration and humoral defense, plays a role in HIV-2 infection and perhaps development of AIDS, lymphoma, myeloma, and leukemia, Genbank Accession No. NP—001707.1);
(30) HLA-DOB (Beta subunit of MHC class II molecule (Ia antigen) that binds peptides and presents them to CD4+T lymphocytes, Genbank Accession No. NP—002111.1);
(31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5, an ion channel gated by extracellular ATP, Genbank Accession No. NP—002552.2);
(32) CD72 (B-cell differentiation antigen CD72, Lyb-2, Genbank Accession No. NP—001773.1);
(33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine richrepeat (LRR) family, regulates B-cell activation and apoptosis, loss of function is associated with increased disease activity in patients with systemic lupus erythematosis, Genbank Accession No. NP—005573.1);
(34) FCRH1 (Fc receptor-like protein 1, a putative receptor for the immunoglobulin Fc domain that contains C2 type Ig-like and ITAM domains, Genbank Accession No. NP—443170.1); and
(35) IRTA2 (Immunoglobulin superfamily receptor translocation associated 2, a putative immunoreceptor with possible roles in B cell development and lymphomagenesis; deregulation of the gene by translocation occurs in some B cell malignancies, Genbank Accession No. NP—112571.1).

### Claim 9 (depends on 6)

The conjugate compound according to claim 6, wherein L is folic acid.

### Claim 10 (depends on 6)

The conjugate compound according to claim 6, wherein L is epidermal growth factor.

### Claim 11 (depends on 1)

The conjugate compound according to claim 1, wherein T is a hydroxyl-containing drug moiety.

### Claim 12 (depends on 1)

The conjugate compound according to claim 1, wherein T is an anticancer agent selected from the group consisting of N8-acetyl spermidine, actinomycin, 9-amino camptothecin, aminopterin, anguidine, anthracycline, auristatin, bleomycin, calicheamycin, camptothecin, carminomycin, CC-1065, clofaribine, 1-(2-chloroethyl)-1,2-dimethanesulfonyl hydrazide, cyclopropabenzindol-4-one (CBI), cytarabine, cytosine arabinoside, daunorubicin, dichloromethotrexate, n-(5,5-diacetoxy-pentyl) doxorubicin, 1,8-dihydroxy-bicyclo[7.3.1]trideca-4-9-diene-2,6-diyne-13-one, difluoronucleosides, doxorubicin, duocarmycin, epirubicin, esperamicin, etoposide, 5-fluorouracil, irinotecan, leurosideine, leurosine, maytansine, melphalan, 6-mercaptopurine, methopterin, methotrexate, mitomycin A, mitomycin C, morpholine-doxorubicin, butyric acid, cisplatin, diacetoxypentyldoxorubicin, maytansinol, capecitabine, leuprolide, bicalutamide, goserelin, 17-AAG, 17-DMAG, des-acetyl vinblastine, nemorubicin, podophyllotoxin, podophyllotoxin derivatives, retinoic acid, saporin, tallysomycin, vinblastine, vincristine, vindesine, taxane, taxol, paclitaxel, taxotere, docetaxel, taxotere retinoic acid, and isomers, salt forms, analogues, and derivatives thereof

### Claim 13 (depends on 1)

The conjugate compound according to claim 1 having the formula:

### Claim 14 (depends on 1)

The conjugate compound according to claim 1 having the formula:

### Claim 15 (depends on 1)

A pharmaceutical composition comprising:
a pharmaceutically acceptable carrier and the conjugate compound according to claim 1.

### Claim 16 (depends on 1)

A method of treating cancer in a patient in need thereof comprising:
selecting a cancer subject in need of treatment, and
administering to the selected subject a therapeutically acceptable amount of a conjugate compound according to claim 1.

### Claim 17 (depends on 16)

The method of treating cancer according to claim 16, wherein the cancer is selected from the group consisting of carcinomas of the bladder, breast, cervix, colon, endometrium, kidney, lung, esophagus, ovary, prostate, pancreas, liver, skin, stomach, and testes.

### Claim 18

A conjugate compound of formula (III):
wherein
L is a cell-targeting ligand;
T is a therapeutic agent, with the proviso that T is not CAS Registry No. 115834-23-6 (SF2446A1) or derivatives or analogues thereof;
J is a linker group, with the proviso that when X is a bond, J cannot directly bond to the silicon atom with an O, NH, N—CH3, S, or carboxyl and forms a hydrolytically stable carbon bond with the silicon atom;
X is independently selected from the group consisting of:
(1) a bond;
(2)
which is independently and optionally substituted from 1 to 2 times with R′5, wherein the wavy lines indicate point of attachment sites and * is the point of attachment to J and ** is the point of attachment to Si; and
(3)
which is independently and optionally substituted from 1 to 2 times with R′5, wherein the wavy lines indicate point of attachment sites and * is the point of attachment to J and ** is the point of attachment to Si;
R13 and R14 are each independently selected from the group consisting of C1-6 alkyl, C3-6 cycloalkyl, aryl, and heteroaryl, each of which is optionally substituted with R16;
R15 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, CN, halogen, NO2, oxo, aryl, heteroaryl, OR17, COOR17, COR17, CONR17R18, COONR17R18, SO2R17, or SO2NR17R18;
R16 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, CN, halogen, NO2, OR17, NR17R18, COOR17, COR17, CONR17R18, SO2R17, —SO2NR17R18, aryl, or heteroaryl;
R17 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, wherein the C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
R18 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, wherein the C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy; or
R17 and R18 are taken together with the nitrogen to which they are attached to form a five- to seven-membered heterocyclic ring, which may be saturated or unsaturated and comprises from 1 to 5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and is optionally substituted from 1 to 4 times with a substituent selected independently at each occurrence thereof from the group consisting of halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 alkoxy; and
v is 1 to 8.

### Claim 19 (depends on 18)

The conjugate compound according to claim 18, wherein J is —Z—Y2—C(O)—Y1—;
Z is
wherein the wavy lines indicate point of attachment sites and * is the point of attachment to L and ** is the point of attachment to Y2;
Y1 is C1-6 alkylene or —(X2—CH2—CH2)l—, each of which is optionally substituted with R8;
Y2 is C1-6 alkylene or —(CH2CH2(X3))q—, each of which is optionally substituted with R8;
X2 is independently selected from the group consisting of:
(1) a bond;
(2) (CH2)k;
(3) O; and
(4) NR12;
X3 is independently selected from the group consisting of:
(1) a bond;
(2) (CH2)k;
(3) O; and
(4) NR12;
R11 is H, C1-6 alkyl, C1-6 hydroxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, aryl, or heteroaryl, each of which is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
R12 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, or C1-6 hydroxyalkyl;
k is 1 to 3;
l is 1 to 10; and
q is 1 to 10.

### Claim 20 (depends on 18)

The conjugate compound according to claim 18, wherein J is —Z—Y3—;
Z is
wherein the wavy lines indicate point of attachment sites and * is the point of attachment to L and ** is the point of attachment to Y3;
Y3 is selected from the group consisting of C1-6 alkylene, C3-C8 carbocyclyl, O(CH2)r, arylene, O(CH2)r-arylene, -arylene-(CH2)r—, (CH2)r—(C3-8 carbocyclyl), —(C3-8 carbocyclyl)-(CH2)r, C3-8 heterocyclyl, (CH2)r—(C3-8 heterocyclyl), —(C3-8 heterocyclyl)-(CH2)r, —((X4)(X5)(CH2)r(X6)(CH2)r)s—, and —((X4)(X5)(CH2)r(X6)(X7)(CH2)r)s—, each of which is optionally substituted with R8;
X4, X5, X6, and X7 are each independently selected from the group consisting of a bond, (CH2)k, O, C(O), S, NR19, C(O)O, and C(O)NR19;
R11 is H, C1-6 alkyl, C1-6 hydroxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, aryl, or heteroaryl, each of which is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
R19 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, or C1-6 hydroxyalkyl;
each r is 0 to 16; and
s is 1 to 10.

### Claim 21 (depends on 18)

The conjugate compound according to claim 18, wherein R13 and R14 are each C1-6alkyl or phenyl.

### Claim 22 (depends on 18)

The conjugate compound according to claim 18, wherein J further comprises a thiol-containing spacer.

### Claim 23 (depends on 18)

The conjugate compound according to claim 18, wherein L is a protein, a peptide, an amino acid, a receptor ligand, a hormone, or a growth factor.

### Claim 24 (depends on 23)

The conjugate compound according to claim 23, wherein L is selected from the group consisting of an antibody, an antibody fragment, scFv-Fc, minibody, diabody, scFv, folic acid, bombesin, EDG, transferrin, gastrin, gastrin-releasing peptide, platelet-derived growth factor, IL-2, IL-6, TFG-alpha, TFG-beta, VGF, insulin, and insulin-like growth factors I and II.

### Claim 25 (depends on 23)

The conjugate compound according to claim 23, wherein L is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(35):
(1) BMPR1B (bone morphogenetic protein receptor-type IB, Genbank Accession No. NM—001203);
(2) E16 (LAT1, SLC7A5, Genbank Accession No. NM—003486);
(3) STEAP1 (six transmembrane epithelial antigen of prostate, Genbank Accession No. NM—012449);
(4) 0772P (CA125, MUC16, Genbank Accession No. AF361486);
(5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin, Genbank Accession No. NM—005823);
(6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b, Genbank Accession No. NM—006424);
(7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5bHlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembranedomain (TM) and short cytoplasmic domain, (semaphorin) 5B, Genbank Accession No. AB040878);
(8) PSCA h1g (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene, Genbank Accession No. AY358628);
(9) ETBR (Endothelin type B receptor, Genbank Accession No. AY275463);
(10) MSG783 (RNF124, hypotheticalproteinFLJ20315, Genbank Accession No. NM—017763);
(11) STEAP2 (HGNC—8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostatecancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelialantigen of prostate 2, six transmembrane prostate protein, Genbank Accession No. AF455138);
(12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potentialcation channel, subfamily M, member 4, Genbank Accession No. NM—017636);
(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor, Genbank Accession No. NP—003203 or NM—003212);
(14) CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs.73792 Genbank Accession No. M26004);
(15) CD79b (CD79B, CD7913, IGb (immunoglobulin-associated beta), B29, Genbank Accession No. NM—000626);
(16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchorprotein 1a), SPAP1B, SPAP1C, Genbank Accession No. NM—030764);
(17) HER2 (Genbank Accession No. M11730);
(18) NCA (Genbank Accession No. M18728);
(19) MDP (Genbank Accession No. BC017023);
(20) IL20Rα(Genbank Accession No. AF184971);
(21) Brevican (Genbank Accession No. AF229053);
(22) Ephb2R (Genbank Accession No. NM—004442);
(23) ASLG659 (Genbank Accession No. AX092328);
(24) PSCA (Genbank Accession No. AJ297436);
(25) GEDA (Genbank Accession No. AY260763);
(26) BAFF-R (B cell-activating factor receptor, BLyS receptor 3, BR3, GenBank Accession No. NP—443177.1);
(27) CD22 (B-cell receptor CD22-B isoform, GenBank Accession No. NP-001762.1);
(28) CD79a (CD79A, CD79a, immunoglobulin-associated alpha, a B cell-specific protein that covalently interacts with Ig beta (CD79B) and forms a complex on the surface with Ig M molecules, transduces a signal involved in B-cell differentiation, Genbank Accession No. NP—001774.1);
(29) CXCR5 (Burkitt's lymphoma receptor 1, a G protein-coupled receptor that is activated by the CXCL13 chemokine, functions in lymphocyte migration and humoral defense, plays a role in HIV-2 infection and perhaps development of AIDS, lymphoma, myeloma, and leukemia, Genbank Accession No. NP—001707.1);
(30) HLA-DOB (Beta subunit of MHC class II molecule (Ia antigen) that binds peptides and presents them to CD4+T lymphocytes, Genbank Accession No. NP—002111.1);
(31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5, an ion channel gated by extracellular ATP, Genbank Accession No. NP—002552.2);
(32) CD72 (B-cell differentiation antigen CD72, Lyb-2, Genbank Accession No. NP—001773.1);
(33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine richrepeat (LRR) family, regulates B-cell activation and apoptosis, loss of function is associated with increased disease activity in patients with systemic lupus erythematosis, Genbank Accession No. NP—005573.1);
(34) FCRH1 (Fc receptor-like protein 1, a putative receptor for the immunoglobulin Fc domain that contains C2 type Ig-like and ITAM domains, Genbank Accession No. NP—443170.1); and
(35) IRTA2 (Immunoglobulin superfamily receptor translocation associated 2, a putative immunoreceptor with possible roles in B cell development and lymphomagenesis; deregulation of the gene by translocation occurs in some B cell malignancies, Genbank Accession No. NP—112571.1).

### Claim 26 (depends on 23)

The conjugate compound according to claim 23, wherein L is folic acid.

### Claim 27 (depends on 23)

The conjugate compound according to claim 23, wherein L is epidermal growth factor.

### Claim 28 (depends on 18)

The conjugate compound according to claim 18, wherein T is a hydroxyl-containing drug moiety.

### Claim 29 (depends on 18)

The conjugate compound according to claim 18, wherein T is an anticancer agent selected from the group consisting of N8-acetyl spermidine, actinomycin, 9-amino camptothecin, aminopterin, anguidine, anthracycline, auristatin, bleomycin, calicheamycin, camptothecin, carminomycin, CC-1065, clofaribine, 1-(2-chloroethyl)-1,2-dimethanesulfonyl hydrazide, cyclopropabenzindol-4-one (CBI), cytarabine, cytosine arabinoside, daunorubicin, dichloromethotrexate, n-(5,5-diacetoxy-pentyl) doxorubicin, 1,8-dihydroxy-bicyclo[7.3.1]trideca-4-9-diene-2,6-diyne-13-one, difluoronucleosides, doxorubicin, duocarmycin, epirubicin, esperamicin, etoposide, 5-fluorouracil, irinotecan, leurosideine, leurosine, maytansine, melphalan, 6-mercaptopurine, methopterin, methotrexate, mitomycin A, mitomycin C, morpholine-doxorubicin, butyric acid, cisplatin, diacetoxypentyldoxorubicin, maytansinol, capecitabine, leuprolide, bicalutamide, goserelin, 17-AAG, 17-DMAG, des-acetyl vinblastine, nemorubicin, podophyllotoxin, podophyllotoxin derivatives, retinoic acid, saporin, tallysomycin, vinblastine, vincristine, vindesine, taxane, taxol, paclitaxel, taxotere, docetaxel, taxotere retinoic acid, and isomers, salt forms, analogues, and derivatives thereof.

### Claim 30 (depends on 18)

The conjugate compound according to claim 18 having the formula:

### Claim 31 (depends on 18)

The conjugate compound according to claim 18 having the formula:

### Claim 32 (depends on 18)

A pharmaceutical composition comprising:
a pharmaceutically acceptable carrier and the conjugate compound according to claim 18.

### Claim 33 (depends on 18)

A method of treating cancer in a patient in need thereof comprising:
selecting a cancer subject in need of treatment, and
administering to the selected subject a therapeutically acceptable amount of a conjugate compound according to claim 18.

### Claim 34 (depends on 33)

The method of treating cancer according to claim 33, wherein the cancer is selected from the group consisting of carcinomas of the bladder, breast, cervix, colon, endometrium, kidney, lung, esophagus, ovary, prostate, pancreas, liver, skin, stomach, and testes.
